QingSong Health Corporation
轻 松 健 康 集 团
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2661)

PROFIT WARNING

This announcement is made by QingSong Health Corporation (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Company and its subsidiaries for the six months ended 30 June 2026 and the information currently available to the Company, the Group is expected to record a loss attributable to shareholders of the Company in the range of approximately RMB40 million to RMB70 million for the six months ended 30 June 2026, as compared to a profit attributable to shareholders of the Company of approximately RMB86.0 million for the six months ended 30 June 2025.

The Group is also expected to record a loss attributable to shareholders of the Company, after excluding non-recurring profit and loss items, in the range of approximately RMB40 million to RMB70 million for the six months ended 30 June 2026, as the amount of such non-recurring items is expected to be insignificant, as compared to a profit attributable to shareholders of the Company, after excluding non-recurring profit and loss items, of approximately RMB51.2 million for the six months ended 30 June 2025.

The expected loss was primarily attributable to the following factors:

(i) The increase in research and development expenses, mainly due to expenses incurred in procuring medical training data, including medical books, medical knowledge graphs, disease knowledge bases, and other medical data, for the training of AI models related to QSevidence, the evidence-based medicine intelligent agent;

(ii) the increase in customer acquisition expenditures for the insurance business as the Company intensified its efforts in acquiring insurance customers; and

(iii) a significant decrease in revenue from the Company's digital marketing services due to reduced budgets and demand from certain major customers.

The Company is in the process of finalising the interim results of the Group for the six months ended 30 June 2026. The information contained in this announcement is only a preliminary assessment made by the Board based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and the information currently available to the Company, and has not been audited or reviewed by the auditors of the Company. Details of the Group's interim results for the six months ended 30 June 2026 will be disclosed in the relevant interim results announcement of the Company when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
QingSong Health Corporation
轻松健康集团
YANG Yin
Chairlady of the Board,
Executive Director
and Chief Executive Officer

Hong Kong, July 17, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Ms. YANG Yin and Mr. GAO Yushi as executive Directors; (ii) Mr. WU Bin as non-executive Director; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Ms. Ji Wenting as independent non-executive Directors.